TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01123655
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment will be stopped or interrupted if indicated. Medical care will be provided at no cost to the patient.
Study: NCT03817268
Drug: Capecitabine monotherapy
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine is administered within 6 weeks after resection and after adequate recovery. To reduce the side effects and improve patient compliance, the administered dose is half of the recommendation: 625 mg/m2, bis in die (BID) (1250 mg/m2 per day). A 2-week therapy is followed by a 1-week pause, and a cycle includes 3 weeks. A total of 8 cycles is planned for each patient.
Study: NCT04675021
Drug: AZD6094 (Savolitinib) film coated tablets 600 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD6094 (Savolitinib) ilm Coated Tablet 200 mg x 3
Study: NCT04675021
Drug: [14C]-AZD6094 (Savolitinib) Solution for Infusion, 20 μg/mL (NMT 37.0 kBq/5 mL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14C AZD6094 (Savolitinib) Solution for Infusion (20 μg/mL (NMT 37.0 kBq/5 mL)
Study: NCT04675021
Drug: [14C] AZD6094 (Savolitinib) Oral Solution, 300 mg (NMT 4.1 MBq)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14CAZD6094 (Savolitinib) Oral Solution (300 mg NMT 4.1MBq)
Study: NCT00567710
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules
Study: NCT01719653
Drug: SUPREP
Normalized name: Suprep Bowel Prep Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUPREP consumed as described in each arm.
Study: NCT00733993
Drug: Caffeine 150 MG
Normalized name: caffeine 150 MG
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Across five separate testing days, subjects were administered two placebo doses, 20 mg amphetamine, 150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
Study: NCT03609047
Drug: Docetaxel / cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant Chemotherapy
Study: NCT03609047
Drug: doxorubicin/cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant Chemotherapy
Study: NCT03609047
Drug: epirubicin/cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant Chemotherapy
Study: NCT03239210
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo equivalent
Study: NCT00733993
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Across five separate testing days, subjects were administered two placebo doses, 20 mg amphetamine, 150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
Study: NCT00733993
Drug: Caffeine 300 MG
Normalized name: caffeine 300 MG
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Across five separate testing days, subjects were administered two placebo doses, 20 mg damphetamine,150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
Study: NCT00107120
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for up to 8 weeks
Study: NCT00718354
Drug: Standard Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's discretion
Study: NCT00892021
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00121056
Drug: Enbrel®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00121056
Drug: Kineret®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03506477
Drug: Enstilar® foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: for 4 weeks
Study: NCT02243657
Drug: ASP3652
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02243657
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT03966066
Drug: erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-5mg/kg.d orally for 6 months
Study: NCT00876928
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: medium chain triglyceride given once per week
Study: NCT03339128
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT02908347
Drug: MP1032
Approvals — FDA: no, EMA: no, PMDA: no
Description: hard gelatine capsules containing 50 mg MP1032 as active ingredient
Study: NCT02908347
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: hard gelatine capsules without active ingredient
Study: NCT00167310
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of Placebo (soy bean oil) in 4 x 500 mg capsules daily for baseline, 1 month, 2 months and 4 months
Study: NCT03306836
Drug: Heparin Sodium
Normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infused with 5000 IU of Heparin Sodium
Study: NCT03306836
Drug: Heparin Sodium
Normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion Heparin Sodium at a rate of 18 IU / kg.h
Study: NCT06004947
Drug: CCX168
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT00350181
Drug: CY
Normalized name: CYT
Approvals — FDA: no, EMA: no, PMDA: no
Description: For subjects aged 18-60 with lymphoma 100 mg/kg, IV For subjects aged with AML, ALL or CML 18-50 60 mg/kg, IV For subjects aged 51-60 with MDS, AML or ALL or patients age 18-60 with MDS, secondary AML or non-CML myeloproliferative disease 45 mg/kg
Study: NCT06004947
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT03802591
Drug: CS1001 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant will receive CS1001 placebo antibody by intravenous infusion every 3 weeks(Q3W), for up to 24 months
Study: NCT03802591
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered by oral, twice a day on Day 1 - Day 14 of each cycle.
Study: NCT02708459
Drug: Bupevecaine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02708459
Drug: Dexmedetomedine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01037244
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets via oral administration before an attempt at sexual intercourse.
Study: NCT04541186
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT00710164
Drug: XSCR capsule (Composed of Traditional Chinese Medicine Huangqi, Chuanxiong, Chishao, Danggui, Dilong, Taoren, Honghua.)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 days of XSCR capsule
Study: NCT00710164
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 days of Placebo
Study: NCT04333927
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (1,330 mg/m2 per day, in divided doses twice daily, 7 days per week).
Study: NCT00537862
Drug: Enteric-Coated Mycophenolate Sodium (EC-MPS)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01224795
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Peramivir, administered intravenously.
Study: NCT00464607
Drug: hMG-IBSA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01502631
Drug: SUN13837 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUN13837 injection, injection 1 x daily for 28 doses
Study: NCT04539977
Drug: TQB2450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inductive therapy: TQB2450 + EC(4 cycles) Maintenance therapy: TQB2450+EC(2 cycles) followed byTQB2450 (1 year)
Study: NCT01502631
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo, volume equivalent to injection 1 x daily for 28 doses
Study: NCT01036802
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02025608
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000498
Drug: antihypertensive agents
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00582790
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid will be given on day 1 intravenously over 15 or 30 minutes starting at 400mcg. If no significant increase in gamma delta-T cell augmentation is seen, the dose of zoledronic acid will be increased in the subsequent cycle up to a maximum dose of 3mg.
Study: NCT02447367
Drug: JLP-1207(Fed)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fed followed by fasted in period 1, the subjects will receive an oral pill of JLP-1207 under fed condition
Study: NCT03904355
Drug: Gonadotropins
Normalized name: GONADOTROPINS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropin stimulation of follicular growth
Study: NCT03043196
Drug: SRP plus Rosuvastatin gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP followed by Rosuvastatin placement into intrabony defect
Study: NCT03043196
Drug: SRP plus placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP followed by placebo gel placement into intrabony defect
Study: NCT02102555
Drug: IV acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of one gram of IV acetaminophen given in pre-operative area
Study: NCT02102555
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (IV normal saline)
Study: NCT02500927
Drug: ASP8273 Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02500927
Drug: ASP8273 Capsules A
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT03229889
Drug: Flomax 0.4Mg Capsule
Normalized name: Flomax 0.4mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin is an alpha-blocker that has been shown to relax smooth muscle in the genitourinary system. Patients will be asked to 1 pill for 7 days prior to surgery.
Study: NCT03229889
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is plant cell based pill that contains no active ingredient. Patients will be asked to 1 pill for 7 days prior to surgery.
Study: NCT00354458
Drug: Comparator: Placebo (unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rolofylline Pbo 30 mg IV QD; 3 days
Study: NCT00840320
Drug: 1278863
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15mg, 25mg, 50mg, 150mg
Study: NCT00840320
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT02201563
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral minocycline (100mg twice a day) for 3 months
Study: NCT00324532
Drug: ProBactrix
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01237678
Drug: IMGN901
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 2 regimen is IMGN901, Carboplatin, and Etoposide. IMGN901 to be given on days 1 and 8 every 21 days.
Study: NCT00482950
Drug: PHX1149T
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03754413
Drug: comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment
Study: NCT03043053
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray
Study: NCT00264212
Drug: irbesartan and irbesartan-hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01627665
Drug: D->R->C+R
Approvals — FDA: no, EMA: no, PMDA: no
Description: one oral dose DABIGATRAN 300 mg -\> RIVAROXABAN 40 mg -\> 1g/day CLARITHOMYCINE with RIVAROXABAN 40 mg
Study: NCT01627665
Drug: D->R->C+D
Approvals — FDA: no, EMA: no, PMDA: no
Description: one oral dose DABIGATRAN 300 mg -\> RIVAROXABAN 40 mg -\> 1g/day CLARITHOMYCINE with one oral dose DABIGATRAN 300 mg
Study: NCT01627665
Drug: R->D->C+D
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIVAROXABAN 40 mg -\> one oral dose DABIGATRAN 300 mg -\> 1g/day CLARITHOMYCINE with one oral dose DABIGATRAN 300 mg
Study: NCT01627665
Drug: R->D->C+R
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIVAROXABAN 40 mg -\> one oral dose DABIGATRAN 300 mg -\> 1g/day CLARITHOMYCINE with RIVAROXABAN 40 mg
Study: NCT00469131
Drug: tacrolimus + mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02139540
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% nitrogen \[inert\]/50% oxygen - otherwise completely identical administration and setup
Study: NCT02845674
Drug: OTX-101 0.09%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.09% cyclosporine nanomicellar solution
Study: NCT00176449
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparable placebo
Study: NCT02966834
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2330672 matching placebo will be supplied as white film-coated tablets.
Study: NCT02966834
Drug: GSK2330672
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2330672 will be supplied in 2 dose strengths of 10 mg and 45 mg white film-coated tablets.
Study: NCT02656160
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 3 hrs before sleep
Study: NCT01931384
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline intramuscularly on the day of embryo transfer and 5 days after embryo transfer.
Study: NCT00296517
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with Major Depressive Disorder who were randomised to placebo to match Bupropion SR during the treatment period.
Study: NCT00333528
Drug: Human butyrylcholinesterase (HuBChE) derived from human plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration
Study: NCT00333528
Drug: Placebo: Normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration
Study: NCT03040193
Drug: Lignocaine Nebulization
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% Lignocaine delivered via Nebulization
Study: NCT01005433
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo group (n = 20) will receive an i.v. infusion of 0.1 mL/kg/h saline 0.9%, at 30 min before induction of anesthesia. The placebo solution will be looked identical and their infusions will be continued until skin closure, when the infusion rate will be decreased by 50% until 20 min after extubation. The test solution will be prepared by one anesthesiologist before induction of anesthesia.
Study: NCT03040193
Drug: Saline Nebulization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline Delivered via Nebulization
Study: NCT03601988
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy group receive 8 cycles of XELOX.
Study: NCT02590809
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given for 30 days
Study: NCT02688361
Drug: Fluimucil® 2% solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be orally administered with 10ml of 2% oral solution of Fluimucil® (reference).
Study: NCT02066545
Drug: CLS001 Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02066545
Drug: CLS001 Topical Gel Vehicle
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03453931
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous high dose corticosteroids
Study: NCT01677039
Drug: Test formulation administered with 20% ethanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of 20 mg of test formulation with 240 mL of 20% ethanol in water
Study: NCT00688961
Drug: omega-3 acid ethyl esters
Normalized name: omega-3 acid ethyl esters
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4, 1 g capsules q.d.
Study: NCT02554396
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline ophthalmic solution
Study: NCT00647348
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80mg simvastatin oral once daily for 24 months
Study: NCT00647348
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo tablet once daily for 24 months
Study: NCT00251758
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
Study: NCT00908934
Drug: AZD9056 formulation Phase III 50 mg (T)
Normalized name: CARDIOTOXIN III
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given as 50 mg tablet (T)
Study: NCT00908934
Drug: AZD9056 formulation Phase IIb 50 mg (R)
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given as 50 mg tablet (R)
Study: NCT00908934
Drug: AZD9056 formulation Phase III 200 mg (T)
Normalized name: CARDIOTOXIN III
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given as 400 mg (2 x 200 mg tablet (T))
Study: NCT02015533
Drug: CR8020
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR8020 50 mg/kg solution will be administered as a single 2-hour intravenous infusion.
Study: NCT00908934
Drug: AZD9056 formulation Phase IIb 200mg (R)
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given as 400 mg (2 x 200 mg tablet (R))
Study: NCT02015533
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as a single 2-hour intravenous infusion.
Study: NCT02829424
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Use of low dose methotrexate (MTX) in psoriasis patients receiving an anti TNF alpha agent
Study: NCT02829424
Drug: Methotrexate Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of placebo- MTX in psoriasis patients receiving anti TNF alpha agent according to the approved indication
Study: NCT00811187
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5cc Normal Saline injection in each paracervical region
Study: NCT02817503
Drug: Standard BP control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target.
Study: NCT02817503
Drug: Moderate BP control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target.
Study: NCT02426099
Drug: Low dose spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week add-on low dose spironolactone in resistant hypertension
Study: NCT00001521
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: reduced hydrocortisone dose can normalize the growth and adult stature of children with congenital adrenal hyperplasia
Study: NCT02033512
Drug: Transdermal Nanoformulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Blood samples were collected from the subjects early in the morning after an overnight fast. After serum testing, the identification hormone deficiencies, was determined and then, if necessary, additional transdermal hormones were prescribed.
Study: NCT02033512
Drug: Transdermal formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 66 patients completed the study. In the present analysis, the subjects received daily in the right and left forearm a transdermal nanostructured formulation of Estriol (0.1%) + Estradiol (0.25%) and Progesterone (10%) respectively (Biolipid B2®, Evidence, SP, Brazil) for sixty months. The effects of transdermal hormone formulation were analyzed.
Study: NCT01621009
Drug: Placebo medication + counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo bupropion once daily 7 days before quit day, then twice daily 4 days before quit attempt, then twice daily for 8 weeks after quit day.~Counseling: Two 10-minutes sessions before quit day, then eight 10-minutes sessions for eight weeks after quit day.
Study: NCT01621009
Drug: Placebo medication, No counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-quit: Placebo medication once daily 7 days before quit day, then twice daily before quit day, then twice daily for 8 weeks after quit day.~Counseling: No counseling, just medication checks
Study: NCT01715051
Drug: D-serine
Normalized name: D-Serine
DrugBank: D-Serine (DB03929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The molecular formula for D-serine is C3H7NO3. D-serine is being used in IND# 71,369 (D Javitt, PI) and in IND#76,940 (H Singer, PI). This approved D-serine will be purchased by the Research Pharmacy at Johns Hopkins and will be encapsulated into capsules containing 500 mg of D-serine.
Study: NCT01715051
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Research Pharmacy at Johns Hopkins will produce matching placebo capsules.
Study: NCT00718705
Drug: Josamycin
Normalized name: josamycin
DrugBank: Josamycin (DB01321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: josamycin with posology of 2 grams per day by oral way during 10 days
Study: NCT04040686
Drug: Injection of 99mTc-NM-02
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will be injected with microdose (\<100ug) of 99mTc-NM-02 radiotracer
Study: NCT00102323
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. Placebo is supplied as a lyophilized power in a 5 mL single use glass vial.
Study: NCT00718705
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with posology of 2 grams per day by oral way during 10 days
Study: NCT02992665
Drug: Ca Ionophore A23187
Normalized name: iodophors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibling oocytes are to be randomized to artificially activated using Calcium ionophore in cases with severely compromized semen parameters
Study: NCT04992442
Drug: [14C]TAK-935 IV Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[14C\]TAK-935 IV infusion
Study: NCT04992442
Drug: [14C]TAK-935 Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[14C\]TAK-935 oral solution
Study: NCT03260283
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 15 mcg of fentanyl will be added to the solution in order to perform subarachnoid anesthesia for urologic operations